Government-Owned Inventions; Availability for Licensing, 51969 [2018-22359]

Download as PDF Federal Register / Vol. 83, No. 199 / Monday, October 15, 2018 / Notices commercialization of results of federally-funded research and development. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health FOR FURTHER INFORMATION CONTACT: National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Arthritis and Musculoskeletal and Skin Diseases Initial Review Group, Arthritis and Musculoskeletal and Skin Diseases Special Grants Review Committee. Date: November 8–9, 2018. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Canopy by Hilton Washington, DC, 940 Rose Avenue, North Bethesda, MD 20852. Contact Person: Helen Lin, Ph.D., Scientific Review Officer, NIH/NIAMS, 6701 Democracy Blvd., Suite 800, Plaza One, Bethesda, MD 20817, 301–594–4952, linh1@ mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.846, Arthritis, Musculoskeletal and Skin Diseases Research, National Institutes of Health, HHS) Dated: October 9, 2018. Sylvia L. Neal, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2018–22310 Filed 10–12–18; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health khammond on DSK30JT082PROD with NOTICES Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious SUMMARY: VerDate Sep<11>2014 21:34 Oct 12, 2018 Jkt 247001 Licensing information may be obtained by emailing the indicated licensing contact at the National Heart, Lung, and Blood, Office of Technology Transfer and Development Office of Technology Transfer, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892–2479; telephone: 301–402–5579. A signed Confidential Disclosure Agreement may be required to receive any unpublished information. SUPPLEMENTARY INFORMATION: Technology description follows. Antibody Targeting Cell Surface Deposited Complement Protein C3d Available for licensing and commercial development is a patent estate covering anti-C3d antibodies, antibody fragments, and their methods of use for killing cancer cells expressing C3d complement protein on their surface, and more particularly for the treatment of patients with Chronic Lymphocytic Leukemia (CLL); a malignancy of mature B-cells and the most common leukemia in the US. The most commonly used monoclonal antibodies (mAbs) are of mouse origin that have been chimerized or humanized to carry human constant regions (typically the human lgG1 isotype), required for the recruitment of human effector mechanisms. The complement system consists of soluble plasma proteins and is activated upon binding of a mAb to target cells resulting in the deposition of complement components on the cell surface and formation of the membrane attack complex (MAC), which can kill cells inducing lysis. The invention originated from an observation during CLL patient treatment with chemotherapy in combination with an anti CD20 mAb (e.g., rituximab or ofatumumab). Upon infusion complement is deposited on the cell surface of CLL cells, a subset of cells is killed, and other cells escape having lost CD20 expression due to a process called trogocytosis by which antibody-CD20 complexes are pulled of the CLL cell surface by immune cells that bind the Fc-portion of the mAb. It has been noted that C3d is stably attached to the CLL cells that escape from further rituximab or ofatumumab targeting and remains detectable for weeks on these cells. C3d, thus, could serve as a neoantigen that could be targeted with anti C3d specific mAbs to kill off escaped tumor cells. Potential Commercial Applications: Development Stage: PO 00000 Frm 00047 Fmt 4703 Sfmt 4703 51969 • Mouse data available. Inventors: Adrian Wiestner, Martin Skarzynski, Christoph Rader (all of NHLBI), and Margaret A. Lindorfer, Ronald P. Taylor, and Berengere Vire (all of the University of Virginia School of Medicine). Relevant Publications: • Robinson, et al. Blood. 2018 Aug 2;132(5):521–532. doi: 10.1182/blood– 2018–02–830992. Intellectual Property: HHS Reference No. E–758–2013–0 and –1; U.S. Provisional Patent Application 61/ 924,967 filed January 8, 2014 (converted), International Patent Application PCT/US2015/010620 filed January 8, 2015 (nationalized), U.S. Patent Application 15/110, 557 filed January 8, 2015, Canadian Patent Application 2936346 filed January 8, 2015, European Patent Application 15701442.4 filed January 8, 2015, and U.S. Divisional Patent Application 16/ 047,929 filed January 8, 2015. Licensing Contact: Michael Shmilovich, Esq, CLP; 301–435–5019; shmilovm@mail.nih.gov. Dated: October 4, 2018. Michael A. Shmilovich, Senior Licensing and Patenting Manager, National Heart, Lung, and Blood Institute, Office of Technology Transfer and Development. [FR Doc. 2018–22359 Filed 10–12–18; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Human Genome Research Institute; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the Center for Inherited Disease Research Access Committee. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Center for Inherited Disease Research Access Committee. Date: November 9, 2018. Time: 11:30 a.m. to 12:30 p.m. Agenda: To review and evaluate grant applications. E:\FR\FM\15OCN1.SGM 15OCN1

Agencies

[Federal Register Volume 83, Number 199 (Monday, October 15, 2018)]
[Notices]
[Page 51969]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-22359]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development.

FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained 
by emailing the indicated licensing contact at the National Heart, 
Lung, and Blood, Office of Technology Transfer and Development Office 
of Technology Transfer, 31 Center Drive Room 4A29, MSC2479, Bethesda, 
MD 20892-2479; telephone: 301-402-5579. A signed Confidential 
Disclosure Agreement may be required to receive any unpublished 
information.

SUPPLEMENTARY INFORMATION: Technology description follows.

Antibody Targeting Cell Surface Deposited Complement Protein C3d

    Available for licensing and commercial development is a patent 
estate covering anti-C3d antibodies, antibody fragments, and their 
methods of use for killing cancer cells expressing C3d complement 
protein on their surface, and more particularly for the treatment of 
patients with Chronic Lymphocytic Leukemia (CLL); a malignancy of 
mature B-cells and the most common leukemia in the US. The most 
commonly used monoclonal antibodies (mAbs) are of mouse origin that 
have been chimerized or humanized to carry human constant regions 
(typically the human lgG1 isotype), required for the recruitment of 
human effector mechanisms. The complement system consists of soluble 
plasma proteins and is activated upon binding of a mAb to target cells 
resulting in the deposition of complement components on the cell 
surface and formation of the membrane attack complex (MAC), which can 
kill cells inducing lysis. The invention originated from an observation 
during CLL patient treatment with chemotherapy in combination with an 
anti CD20 mAb (e.g., rituximab or ofatumumab). Upon infusion complement 
is deposited on the cell surface of CLL cells, a subset of cells is 
killed, and other cells escape having lost CD20 expression due to a 
process called trogocytosis by which antibody-CD20 complexes are pulled 
of the CLL cell surface by immune cells that bind the Fc-portion of the 
mAb. It has been noted that C3d is stably attached to the CLL cells 
that escape from further rituximab or ofatumumab targeting and remains 
detectable for weeks on these cells. C3d, thus, could serve as a 
neoantigen that could be targeted with anti C3d specific mAbs to kill 
off escaped tumor cells.
    Potential Commercial Applications:
    Development Stage:
     Mouse data available.
    Inventors: Adrian Wiestner, Martin Skarzynski, Christoph Rader (all 
of NHLBI), and Margaret A. Lindorfer, Ronald P. Taylor, and Berengere 
Vire (all of the University of Virginia School of Medicine).
    Relevant Publications:
     Robinson, et al. Blood. 2018 Aug 2;132(5):521-532. doi: 
10.1182/blood-2018-02-830992.
    Intellectual Property: HHS Reference No. E-758-2013-0 and -1; U.S. 
Provisional Patent Application 61/924,967 filed January 8, 2014 
(converted), International Patent Application PCT/US2015/010620 filed 
January 8, 2015 (nationalized), U.S. Patent Application 15/110, 557 
filed January 8, 2015, Canadian Patent Application 2936346 filed 
January 8, 2015, European Patent Application 15701442.4 filed January 
8, 2015, and U.S. Divisional Patent Application 16/047,929 filed 
January 8, 2015.
    Licensing Contact: Michael Shmilovich, Esq, CLP; 301-435-5019; 
[email protected].

    Dated: October 4, 2018.
Michael A. Shmilovich,
Senior Licensing and Patenting Manager, National Heart, Lung, and Blood 
Institute, Office of Technology Transfer and Development.
[FR Doc. 2018-22359 Filed 10-12-18; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.